Psychedelic Alpha provides independent data-driven reporting and analysis in the psychedelics space, including consultancy and advisory services for investors and entrepreneurs.

Psychedelic Alpha

Trippy.me offers videos and art focused on trippy and psychedelic themes, self-described as a platform for such content.

Trippy.me

Psychedelic Alpha | 6,745 followers on LinkedIn. Independent data-driven reporting, analysis and commentary on the psychedelics space. | The definitive resource for analysis of the emergent psychedelic medicine sector. Cut through the noise with exclusive news, interviews, data and opportunities.

Founder at Psychedelic Alpha - Commentary, Consultancy, Community for the psychedelics industry

Josh Hardman

Investigative Reporter | Psychedelic politics and public policy analysis from between the aisles and beyond.

Jack Gorsline

Patent Analyst at Calyx Law | JD Candidate at UCalgary Law (2027)

Noah Smith

Explore the topline results from the latest in our series of psychedelics investor surveys. https://lnkd.in/eWaiE8cT

Psychedelics on the Ballot 2024. Follow the latest from Massachusetts and Oregon, where voters are deciding on psychedelics-related measures. ∎ https://lnkd.in/gtGgNzAi

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control; A Look at the Latest Oregon Psilocybin Services Complaints https://lnkd.in/ebYDmNUC

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question 4 In this Opinions piece, Dr. Fernando Espi Forcen, a Massachusetts-based psychiatrist, medical director and assistant professor in psychiatry, responds to what he deems to be three of the most common misconceptions around Question 4. That question, if endorsed by voters next Tuesday, would decriminalise certain psychedelics and establish a state-regulated system of legal psychedelic services. https://lnkd.in/eys65PhR

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff https://lnkd.in/evSPMpyA

Pα+ Psychedelic Bulletin 178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question https://lnkd.in/esTSDcQK

Natural Medicine Advisory Bulletin 14: Vicente LLP looks at big-picture questions as the program hurtles towards launch. First up are fees and rule changes, before the firm reviews Natural Medicine-related meetings since our last Bulletin in late August. https://lnkd.in/eTXjf9FR

Psychedelics Take Centre Stage in Massachusetts’ Local Media: Q4 Pros and Foes square off in ballot question debate series. https://lnkd.in/eznNeaPE

Next month, Massachusetts will vote on Question 4, which would establish a regulated psychedelics program in the state. Right now, it's too close to call with polls showing opinions are within the margin of error. What do you think will be the outcome?

Exclusive: David Hough on Lykos’ Path to Resubmission In this exclusive interview, our Editor Josh Hardman sat down with Hough to discuss how his experience in developing Spravato to eventual approval might inform any future clinical development of MDMA, Hough’s thoughts about the FDA’s verdict and the AdComm that preceded it, what a future Phase 3 program might look like, and more. https://lnkd.in/gSJEz6GU

Metric
Company Name	Psychedelic Alpha	Trippy.me
Symbol
MSH ID	COM:PSYCHEDELICALPHA	ME:TRIPPY
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Services
Industry	Pharmaceuticals & Biotechnology	Entertainment
Country	US	US
Stage		Series A
Employee Count
Website	psychedelicalpha.com	trippy.me
LinkedIn	psychedelicalpha
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		398.45K
Web Traffic Growth		-0.15
Valuation
Raised Capital		3.50M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PSYC

COM:PSYCHEDELICALPHA

Psychedelic Alpha

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue